Esperion Therapeutics Inc (ESPR)

Nov 18, 2024

Esperion Highlights New Exploratory Data from CLEAR - GlobeNewswire

Nov 18, 2024

Nov 15, 2024

Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat

Nov 15, 2024

Nov 14, 2024

ESPR: 3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket - StockNews.com

Nov 14, 2024

Nov 14, 2024

Two Seas Capital LP Acquires Significant Stake in Esperion Thera - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Esperion Therapeutics: Growth Initiatives Are Paying OffBuy - Seeking Alpha

Nov 13, 2024

Nov 13, 2024

Esperion Therapeutics Q3 2024 Earnings Preview - MSN

Nov 13, 2024

Nov 11, 2024

What is HC Wainwright's Estimate for ESPR FY2025 Earnings? - MarketBeat

Nov 11, 2024

Nov 09, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Nov 08, 2024

Nov 08, 2024

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 08, 2024

Nov 08, 2024

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... By GuruFocus - Investing.com Canada

Nov 08, 2024

Nov 08, 2024

Esperion Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 08, 2024

Nov 07, 2024

Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Nov 07, 2024

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times

Nov 07, 2024

Nov 07, 2024

Esperion Q3 Revenue Surges 52% to $51.6M as Prescription Growth Accelerates | ESPR Stock News - StockTitan

Nov 07, 2024

Nov 07, 2024

StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Buy" - MarketBeat

Nov 07, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire

Nov 04, 2024

Oct 31, 2024

Esperion Announces a Featured Presentation in the Late - GlobeNewswire

Oct 31, 2024

Oct 31, 2024

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Oct 31, 2024

Oct 31, 2024

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian

Oct 31, 2024

Oct 31, 2024

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance

Oct 31, 2024

Oct 31, 2024

Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024

Oct 26, 2024

StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat

Oct 26, 2024

Oct 24, 2024

Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire

Oct 24, 2024

Oct 24, 2024

ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 24, 2024

Oct 23, 2024

Nexletol From Esperion - Pharmacy Times

Oct 23, 2024

Oct 18, 2024

Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com

Oct 18, 2024

Oct 18, 2024

Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK

Oct 18, 2024

Oct 17, 2024

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance

Oct 17, 2024

Oct 17, 2024

INVA: 3 Small-Cap Biotech Stocks With Game-Changing Potential - StockNews.com

Oct 17, 2024

Oct 11, 2024

Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat

Oct 11, 2024

Oct 10, 2024

Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat

Oct 10, 2024

Oct 09, 2024

Betty Jean (BJ) Swartz | Management - Esperion Therapeutics

Oct 09, 2024

Oct 05, 2024

Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com - MarketBeat

Oct 05, 2024

Oct 04, 2024

Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cut by Analyst - MarketBeat

Oct 04, 2024

Oct 03, 2024

Esperion shares reiterate Buy rating on trial data By Investing.com - Investing.com South Africa

Oct 03, 2024

Oct 03, 2024

Esperion shares reiterate Buy rating on trial data - Investing.com India

Oct 03, 2024

Oct 03, 2024

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? - Insider Monkey

Oct 03, 2024

Oct 02, 2024

Esperion reports LDL-C reduction success in MILOS study By Investing.com - Investing.com South Africa

Oct 02, 2024

Oct 02, 2024

Esperion reports LDL-C reduction success in MILOS study - Investing.com

Oct 02, 2024

Oct 02, 2024

Esperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 02, 2024

Oct 02, 2024

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid - The Manila Times

Oct 02, 2024